A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

NCT05668403

Status	RECRUITING
Phase	Phase 1
Sponsor	Shanghai Jiaolian Drug Research and Development Co., Ltd
Enrollment	52 participants

Key Eligibility Criteria

Inclusion (6)

- Subjects who have fully understood this study and voluntarily signed the informed consent form;
- Male or female subjects, aged between 18 and 75 years;
- Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy;
- Subjects with systolic blood pressure d 140 mmHg and diastolic blood pressure d 90 mmHg at screening;
- If taking ACEI(Angiotensin converting enzyme inhibitors), ARB(Angiotensin receptor blocker), a stable dose within 4 weeks before screening is required;

... and 1 more (see full listing online)

Exclusion (15)

- Subjects with secondary membranous nephropathy;
- Subjects with uncontrolled blood pressure as judged by the investigator within 3 months before screening;
- Subjects with decreases in urine protein e 50% within 6 months before screening;
- Subjects who have received or are receiving renal replacement therapy;
- Subjects with type 1 diabetes mellitus, or those with type 2 diabetes mellitus who are diagnosed as diabetic nephropathy by percutaneous renal biopsy;

... and 10 more (see full listing online)

Locations (6 total)

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, He'nan, China
Hebei General Hospital, Shijiazhuang, Hebei, China
The First Affiliated Hospital,College of Medicine,Zhejiang University, Hangzhou, Zhejiang, China
... and 3 more locations